Analysis of Blood-based Biomarkers of Asthma

Asthma Clinical Trial

— ABBA  

Official title:

Analysis of Blood-based Biomarkers of Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00917787
• Other study ID #: H6788-34128-01
• Status: Completed
• Start date: June 2009
• Est. completion date: April 2011

Study information

• Verified date: August 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to analyze markers of inflammation in blood and in induced sputum for the purpose of identifying molecular markers of specific asthma phenotypes. The investigators' specific interest is demonstrating that periostin levels are higher than normal in blood. The investigators already have solid preliminary data to support this hypothesis, and our goal here is to replicate preliminary findings and extend them by examining further the characteristics of the asthma subgroup with elevated periostin levels.

Description:

This is a cross-sectional study in patients with asthma and healthy controls in which we will analyze markers of inflammation in blood and in induced sputum for the purpose of identifying molecular markers of specific asthma phenotypes. Our specific interest in demonstrating that periostin levels are higher than normal in blood. We already have solid preliminary data to support this hypothesis, and our goal here is to replicate preliminary findings and extend them by examining further the characteristics of the asthma subgroup with elevated periostin levels. In this regard, we propose detailed phenotyping of the asthmatic subjects and the healthy controls, including measures in induced sputum, exhaled air and detailed physiologic measures including measures of airflow, lung volumes, and methacholine responsiveness. In earlier work we have found that periostin is a marker of Th-2 driven asthma, and we will use the data collected here to further explore this possibility. The biospecimens collected here will also allow us to expand existing plasma, DNA, RNA, and sputum samples in the UCSF Airway tissue bank, so that we can continue to build this resource for future research questions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 127
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Asthmatic Subjects Inclusion criteria

1. Male and female subjects between the ages of 18 and 70 years with a history of asthma who may or may not be taking inhaled corticosteroids for asthma control.

2. Physician diagnosis of asthma

3. PC20FEV1 methacholine = 8.0 mg/mL, except for those taking daily inhaled corticosteroids, for which the PC20 methacholine should be < 16 mg/mL.

4. Ability to provide informed consent.

Healthy Subjects Inclusion criteria

1. Healthy male and female subjects with no history of asthma between the ages of 18 and 70 years. Subjects should not be taking inhaled or oral corticosteroids.

2. No lifetime history of asthma or allergic rhinitis.

3. Ability to provide informed consent.

Exclusion Criteria for both subject groups

1. Lung disease other than asthma.

2. History of an upper or lower respiratory tract infection in the 4 weeks preceding the study.

3. Females who are pregnant or breast-feeding

4. Subjects must be non-smokers (patients who have never smoked or patients who have smoked =5 cigarettes per month and have a total pack-year smoking history < 10 packs).

5. Use of marijuana >1 time per month in the last year and use of marijuana in the 6 weeks prior to enrollment

6. Use of recreational drugs other than marijuana in the 12 months preceding the study.

7. Use of Beta blocker medications

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
United States	UCSF Airway Clinical Research Center	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	periostin levels in blood		1 week